Etoricoxib
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Etoricoxib: From Inflammatory and Pain Conditions to Migraine Disorder
One-Sentence Summary
Etoricoxib is a selective COX-2 inhibitor used for pain and inflammatory conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain and gout. The TxGNN model predicts it may be effective for migraine disorder, but there are no registered clinical trials and only 1 loosely related publication (a scoping review that contains no etoricoxib-specific data). The prediction is therefore supported mainly by the model score and a plausible mechanism, not by direct clinical evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the India licence records; pharmacology references list rheumatoid arthritis, osteoarthritis, chronic lower back pain, ankylosing spondylitis, acute pain and gout |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9990 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Etoricoxib is known as a selective COX-2 inhibitor (target: PTGS2), and its efficacy in pain and inflammatory conditions is established.
COX-2-derived prostaglandins such as PGE2 are thought to contribute to neurogenic inflammation and trigeminovascular sensitization in migraine. Other NSAIDs are established in acute migraine treatment, so a mechanistic link is plausible.
However, the only publication linked to this prediction is a scoping review of fasting-induced headache during Ramadan, which provides no etoricoxib efficacy data. The high TxGNN score is a model prediction only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 42841395 | 2026 | Review | Pain management | Scoping review of fasting-induced headache in Ramadan; no etoricoxib-specific efficacy data |
Related evidence for neighbouring predictions (not direct support for migraine disorder):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29209105 | 2017 | Preclinical (rat) | Mediators of inflammation | Oral nimesulide, etoricoxib and ketoprofen affected CGRP and PGE2 release from rat trigeminal ganglia (predicted indication: migraine susceptibility) |
| 35277974 | 2022 | Case series | Headache | Etoricoxib- and celecoxib-sensitive indomethacin-responsive headache disorders, including trigeminal autonomic cephalalgias |
| 36893522 | 2023 | Case report | Clin Neurol Neurosurg | Two patients with secondary cough headache responded to etoricoxib |
| 17883876 | 2007 | Case report | J Med Case Rep | Etoricoxib used to treat idiopathic stabbing headache |
| 18171381 | 2008 | Case report/small series | Eur J Neurol | Primary stabbing headache can respond to etoricoxib |
India Market Information
Etoricoxib has 20 valid single-ingredient registrations. The records do not include approved indication text. Five representative authorizations:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 80717 | Etix 90mg Tablet | Strip of 10 tablets | Not listed |
| 224464 | Torcoxia 60mg Tablet | Strip of 10 tablets | Not listed |
| 78259 | Etobert 120mg Tablet | Strip of 10 tablets | Not listed |
| 5195 | Adetor 90mg Tablet | Strip of 10 tablets | Not listed |
| 76076 | Etonext 120mg Tablet | Strip of 10 tablets | Not listed |
All products are oral tablets. Several are fixed-dose combinations, for example with thiocolchicoside, paracetamol or tizanidine.
Safety Considerations
- Hyperkalemia and kidney injury: A case report describes life-threatening hyperkalemia and acute kidney dysfunction with etoricoxib in a patient taking telmisartan on a potassium-rich, low-sodium diet.
- Cerebrovascular risk: A case report describes reversible cerebral vasoconstriction syndrome possibly induced by etoricoxib. This is relevant to any headache indication.
- Cardiovascular risk: COX-2 inhibitors have been linked to increased risk of myocardial infarction, fluid retention and raised blood pressure.
- Drug interactions: Pharmacology data identify COX-2 (PTGS2) as the target. No specific drug-drug interaction entries were available.
Please also refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is at the model-prediction level (L5): there are no clinical trials and no etoricoxib-specific migraine data. The mechanism is plausible, but the safety signals, including cardiovascular, renal and cerebrovascular events, need to be weighed.
Of the other predictions, headache disorder and trigeminal autonomic cephalalgia have more direct supporting reports (all case-level, L4) and are better candidates for further research than migraine itself.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India regulator
- Detailed mechanism of action data
- Etoricoxib-specific controlled studies in migraine, or a systematic search of the migraine literature on COX-2 inhibitors
- A cardiovascular, renal and cerebrovascular risk assessment for the target population
- Consideration of headache disorders responsive to COX-2 inhibitors as a more evidence-supported starting point
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.